Gastrointestinal endoscopyOct 10, 2024

Repeat upper digestive tract exams in non-diabetic adults prescribed GLP-1 receptor agonists

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

No significant difference in repeat endoscopy rates was observed between adults taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) and those not taking them.

Repeat endoscopy occurred in 5.4% of GLP-1RA users compared to 4.2% of non-users.
The risk ratio for repeat endoscopy was 1.28, indicating no substantial difference.
New diagnoses of gastroparesis were 1.1% in the GLP-1RA group versus 0.6% in the control group.
The risk ratio for new diagnosis of gastroparesis was 2.00, suggesting no significant increase in risk.

Simplified

BACKGROUND AND AIMS: Data on endoscopic outcomes in adults without diabetes who are taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) are limited. Therefore, we compared repeat EGD in this population with those not taking GLP-1RAs using a retrospective matched case-control study.

METHODS: Using the TriNetX health research platform (Cambridge, Mass, USA), we analyzed adults with a body mass index ≥27 kg/mwithout diabetes who underwent diagnostic EGD. The study group included individuals with ≥3 GLP-1RA prescriptions and undergoing EGD ≥30 days after the initial GLP-1RA prescription. The control group included individuals who were never prescribed GLP-1RAs but had an EGD after the prescription of other weight loss medications. Outcomes were compared using the risk ratio (RR) in matched cohorts. 2

RESULTS: No significant difference in repeat EGD (5.4% vs 4.2%; RR, 1.28; 95% confidence interval [CI], .95-1.71) or new diagnosis of gastroparesis (1.1% vs .6%; RR; 2.00; 95% CI, .94-4.27) was noted between the groups.

CONCLUSIONS: GLP-1RAs may not substantially increase the risk of repeat endoscopy in individuals without diabetes.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Disclosure The following author disclosed financial relationship: D. C. Kaelber is a consultant with Dynavax Technologies Corporation. All other authors disclosed no financial relationships.

PubMed

Repeat upper digestive tract exams in non-diabetic adults prescribed GLP-1 receptor agonists

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief